These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1450 related items for PubMed ID: 14762857

  • 21. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.
    Chuang WL, Dai CY, Chang WY, Lee LP, Lin ZY, Chen SC, Hsieh MY, Wang LY, Yu ML.
    Antivir Ther; 2005; 10(1):125-33. PubMed ID: 15751770
    [Abstract] [Full Text] [Related]

  • 22. Incidence, risk factors, and outcome of chronic rejection during antiviral therapy for posttransplant recurrent hepatitis C.
    Fernández I, Ulloa E, Colina F, Abradelo M, Jiménez C, Gimeno A, Meneu JC, Lumbreras C, Solís-Herruzo JA, Moreno E.
    Liver Transpl; 2009 Aug; 15(8):948-55. PubMed ID: 19642125
    [Abstract] [Full Text] [Related]

  • 23. A pilot study: longer duration of posttransplant hepatitis C virus therapy may increase the sustained response rate.
    Karasu Z, Akay S, Yilmaz F, Akarca U, Ersoz G, Gunsar F, Kilic M.
    Transplant Proc; 2009 Nov; 41(9):3806-9. PubMed ID: 19917392
    [Abstract] [Full Text] [Related]

  • 24. Non-interferon-based therapy: an option for amelioration of necro-inflammation in hepatitis C patients who cannot afford interferon therapy.
    El-Zayadi AR, Attia M, Badran HM, El-Tawil A, Zalata K, Barakat E, Selim O, El-Nakeeb A, Saied A.
    Liver Int; 2005 Aug; 25(4):746-51. PubMed ID: 15998425
    [Abstract] [Full Text] [Related]

  • 25. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C.
    Radkowski M, Gallegos-Orozco JF, Jablonska J, Colby TV, Walewska-Zielecka B, Kubicka J, Wilkinson J, Adair D, Rakela J, Laskus T.
    Hepatology; 2005 Jan; 41(1):106-14. PubMed ID: 15619235
    [Abstract] [Full Text] [Related]

  • 26. Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin.
    Hoofnagle JH, Ghany MG, Kleiner DE, Doo E, Heller T, Promrat K, Ong J, Khokhar F, Soza A, Herion D, Park Y, Everhart JE, Liang TJ.
    Hepatology; 2003 Jul; 38(1):66-74. PubMed ID: 12829988
    [Abstract] [Full Text] [Related]

  • 27. The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C.
    Chemello L, Cavalletto L, Bernardinello E, Guido M, Pontisso P, Alberti A.
    J Hepatol; 1995 Jul; 23 Suppl 2():8-12. PubMed ID: 8720287
    [Abstract] [Full Text] [Related]

  • 28. A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation.
    Gane EJ, Lo SK, Riordan SM, Portmann BC, Lau JY, Naoumov NV, Williams R.
    Hepatology; 1998 May; 27(5):1403-7. PubMed ID: 9581698
    [Abstract] [Full Text] [Related]

  • 29. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
    Saab S, Hunt DR, Stone MA, McClune A, Tong MJ.
    Liver Transpl; 2010 Jun; 16(6):748-59. PubMed ID: 20517909
    [Abstract] [Full Text] [Related]

  • 30. Combined therapy with interferon and low-dose ribavirin in posttransplantation recurrent hepatitis C: a pragmatic study.
    Alberti AB, Belli LS, Airoldi A, de Carlis L, Rondinara G, Minola E, Vangeli M, Cernuschi A, D'Amico M, Forti D, Pinzello G.
    Liver Transpl; 2001 Oct; 7(10):870-6. PubMed ID: 11679985
    [Abstract] [Full Text] [Related]

  • 31. Advances in the treatment of hepatitis C.
    Lawrence SP.
    Adv Intern Med; 2000 Oct; 45():65-105. PubMed ID: 10635046
    [Abstract] [Full Text] [Related]

  • 32. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover.
    Zeuzem S, Schmidt JM, Lee JH, von Wagner M, Teuber G, Roth WK.
    Hepatology; 1998 Jul; 28(1):245-52. PubMed ID: 9657119
    [Abstract] [Full Text] [Related]

  • 33. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation.
    Stravitz RT, Shiffman ML, Sanyal AJ, Luketic VA, Sterling RK, Heuman DM, Ashworth A, Mills AS, Contos M, Cotterell AH, Maluf D, Posner MP, Fisher RA.
    Liver Transpl; 2004 Jul; 10(7):850-8. PubMed ID: 15237368
    [Abstract] [Full Text] [Related]

  • 34. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus.
    Berenguer J, Alvarez-Pellicer J, Martín PM, López-Aldeguer J, Von-Wichmann MA, Quereda C, Mallolas J, Sanz J, Tural C, Bellón JM, González-García J, GESIDA3603/5607 Study Group.
    Hepatology; 2009 Aug; 50(2):407-13. PubMed ID: 19575364
    [Abstract] [Full Text] [Related]

  • 35. Hepatitis C virus in the transplant setting.
    Berenguer M, Wright TL.
    Antivir Ther; 1998 Aug; 3(Suppl 3):125-36. PubMed ID: 10726062
    [Abstract] [Full Text] [Related]

  • 36. Recurrent hepatitis C virus infection after liver transplantation--long-term follow-up with respect to the HCV genotypes/subtypes.
    Arnold JC, Töx U, Goeser T, Otto G, Müller HM, Hofmann WJ, Stremmel W, Theilmann L.
    Z Gastroenterol; 1997 Apr; 35(4):255-61. PubMed ID: 9163889
    [Abstract] [Full Text] [Related]

  • 37. Preemptive antiviral treatment for hepatitis C virus after living donor liver transplantation.
    Sugawara Y, Tamura S, Yamashiki N, Kaneko J, Aoki T, Sakamoto Y, Hasegawa K, Kokudo N.
    Transplant Proc; 2012 Apr; 44(3):791-3. PubMed ID: 22483497
    [Abstract] [Full Text] [Related]

  • 38. Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence.
    Bizollon T, Ahmed SN, Radenne S, Chevallier M, Chevallier P, Parvaz P, Guichard S, Ducerf C, Baulieux J, Zoulim F, Trepo C.
    Gut; 2003 Feb; 52(2):283-7. PubMed ID: 12524414
    [Abstract] [Full Text] [Related]

  • 39. [Is there a place for ribavirin in the treatment for renal transplant patients infected by hepatitis C virus?].
    Kamar N, Sandres-Saune K, Selves J, Durand D, Izopet J, Rostaing L.
    Nephrologie; 2003 Feb; 24(2):89-94. PubMed ID: 12723514
    [Abstract] [Full Text] [Related]

  • 40. Interferon therapy in HCV-positive mixed cryoglobulinaemia: viral and host factors contributing to efficacy of the therapy.
    Mazzaro C, Carniello GS, Colle R, Doretto P, Mazzi G, Crovatto M, Santini GF, Tulissi P, Gregoretti M, Mazzoran L, Russo A, Silvestri F, Pozzato G.
    Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):343-50. PubMed ID: 9476189
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 73.